Working... Menu

Post Transplant Donor Lymphocyte Infusion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00167180
Recruitment Status : Completed
First Posted : September 14, 2005
Results First Posted : July 11, 2017
Last Update Posted : December 5, 2017
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota

Tracking Information
First Submitted Date  ICMJE September 9, 2005
First Posted Date  ICMJE September 14, 2005
Results First Submitted Date April 28, 2017
Results First Posted Date July 11, 2017
Last Update Posted Date December 5, 2017
Study Start Date  ICMJE January 2004
Actual Primary Completion Date March 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 9, 2017)
Number of Patients Alive [ Time Frame: 1 Year ]
The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate. Overall survival will be defined as time from date of enrollment to date of death or censored at the date of last documented contact for patients still alive.
Original Primary Outcome Measures  ICMJE
 (submitted: September 9, 2005)
one year survival
Change History Complete list of historical versions of study NCT00167180 on Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: June 9, 2017)
  • Number of Patients Alive Without Disease [ Time Frame: 1 Year ]
    The number of patients alive one year after treatment without any signs or symptoms of the cancer being treated or any other type of cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works.
  • Number of Participants With Complete Remission [ Time Frame: one year ]
    In complete remission, all signs and symptoms of cancer that can be detected with modern technology have disappeared, although cancer still may be in the body.
  • Number of Patients With Acute Graft-Versus-Host Disease [ Time Frame: Day 100 ]
    Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.
  • Number of Patients With Bone Marrow Aplasia [ Time Frame: Day 100 ]
    Aplastic anemia is a disorder in which the bone marrow greatly decreases or stops production of blood cells. In aplastic anemia, the basic structure of the marrow becomes abnormal, and those cells responsible for generating blood cells (hematopoietic cells) are greatly decreased in number or absent. These hematopoietic cells are replaced by large quantities of fat.
Original Secondary Outcome Measures  ICMJE
 (submitted: September 9, 2005)
  • disease-free survival at one year
  • complete remission at one year
  • acute GVHD by day 100
  • marrow aplasia
Current Other Outcome Measures  ICMJE Not Provided
Original Other Outcome Measures  ICMJE Not Provided
Descriptive Information
Brief Title  ICMJE Post Transplant Donor Lymphocyte Infusion
Official Title  ICMJE Use of Cyclophosphamide/Fludarabine to Promote in Vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy After Allogeneic Transplant
Brief Summary The purpose of this study is to test the hypothesis that a pre-infusion preparative regimen of cyclophosphamide and fludarabine will improve the effectiveness of DLI in patients with blood cancers.
Detailed Description When cancer relapses after donor bone marrow transplantation, regular dose chemotherapy offers little hope of prolonged survival. However, there is evidence that lymphocytes can attack cancer cells. There is considerable evidence that this immune attack on cancer cells is associated with graft-versus-host disease. Although graft-versus-host disease can cause problems, this immune reaction may, in part, be the way that bone marrow transplantation cures cancer. In this study we hope that infusion of immune cells from the subject's bone marrow donor plus a chemotherapy regimen of cyclophosphamide and fludarabine will activate the subject's immune system to attack their cancer.
Study Type  ICMJE Interventional
Study Phase Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Leukemia, Myeloid, Chronic
  • Lymphomas
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Leukemia, Lymphocytic, Acute
  • Leukemia, Lymphocytic, Chronic
  • AML
Intervention  ICMJE
  • Procedure: Donor Lymphocyte Infusion
    donor cells infused over 2 hrs at cell dose of 0.5 dx 10^8 CD3+T-cells/kg
    Other Name: DLI
  • Drug: Induction Chemotherapy
    Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV
    Other Names:
    • Fludara
    • Endoxan, Cytoxan, Neosar, Procytox, Revimmune, cytophosphane
Study Arms
  • Active Comparator: CML
    Patients with Chronic Myelogenous Leukemia (CML) who have failed or refused Gleevec(TM) therapy and will receive Donor Lymphocyte Infusion.
    Intervention: Procedure: Donor Lymphocyte Infusion
  • Active Comparator: Non-CML or CML that Relapsed after Donor Lymphocyte Infusion
    Patients with non-CML or CML who have failed Donor Lymphocyte Infusion (DLI) and will receive induction chemotherapy plus DLI.
    • Procedure: Donor Lymphocyte Infusion
    • Drug: Induction Chemotherapy
Publications * Miller JS, Weisdorf DJ, Burns LJ, Slungaard A, Wagner JE, Verneris MR, Cooley S, Wangen R, Fautsch SK, Nicklow R, Defor T, Blazar BR. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood. 2007 Oct 1;110(7):2761-3. Epub 2007 Jun 19.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 9, 2017)
Original Enrollment  ICMJE
 (submitted: September 9, 2005)
Actual Study Completion Date March 2016
Actual Primary Completion Date March 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients (age > or = 1 years) with a diagnosis of relapse after related or unrelated allogeneic stem cell transplantation for a hematological malignancy.
  • For CML, relapse will be defined as any cytogenetic evidence of a Philadelphia chromosome or persistence of BCR/ABL rearrangements by molecular testing on at least two measurements over a 6 month interval. If cytogenetics are normal and there is PCR evidence of a BCR/ABL fusion, patients will be eligible if they have evidence of a quantitative increase in CML measured either by quantitative PCR or by fluorescent in situ hybridization (FISH).
  • For non-CML, relapse will be defined based on disease specific morphologic criteria from a bone marrow biopsy and aspirate or recurrence of disease specific cytogenetics. For disease specific definition of relapse, see appendix 3. Relapse can be determined morphologically with less than 5 percent blasts if definitive relapse can be determined. Equivocal results for relapse should result in a repeated test after an appropriate time interval (suggested 1 month) to determine eligibility.

Post-transplant lymphoproliferative diseases (often referred to as EBV-associated lymphomas) are NOT eligible for this protocol.

  • For Chronic Phase CML patients only
  • - must have failed (no response in 3 months or incomplete response at 6 months) or refused treatment with Gleevec
  • - if no prior DLI, CML patients will first have DLI- if relapse occurs after DLI, DLI with chemotherapy per this protocol will be offered
  • Patients must be within one year of identification of relapse or if beyond that time period, must have at least 10% donor DNA by RFLP or cytogenetics.
  • Same allogeneic donor (sibling or URD) used for transplantation is available for lymphocyte donation.
  • No severe organ damage (by laboratory or clinical assessment) as measured by:
  • - blood creatinine ≤ 2.0 mg/dL
  • - liver function tests < 5 x normal
  • - left ventricular ejection fraction > 40% (testing required only if symptomatic or prior known impairment).
  • - pulmonary functions > 50% (testing required only if symptomatic or prior known impairment). Oxygen saturation (>92%) can be used in child where PFT's cannot be obtained.
  • - chest x-ray without evidence of active infection
  • Off prednisone and other immunosuppressive agents (given for any reason) for at least 3 days prior to DLI infusions.
  • Performance status ≥ 60%
  • Women must not be pregnant or lactating. The agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy
  • Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraception
  • Patient must given written informed consent indicating understanding of the nature of the treatment and its potential risks

Exclusion Criteria:

  • Concurrent signs of acute or chronic graft-versus-host disease requiring ongoing treatment at the time of relapse will be ineligible.
  • Patients being treated for GVHD with prednisone, cyclosporine, Imuran or other immunosuppressive medications are not eligible until these medications are discontinued for at least 2 weeks without a flare of GVHD.
  • Active CNS leukemia
  • Active fungal infection or pulmonary infiltrates (stable prior treated disease is allowable)
  • HIV positive
Sexes Eligible for Study: All
Ages 1 Year to 70 Years   (Child, Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00167180
Other Study ID Numbers  ICMJE 2004LS006
MT2003-15 ( Other Identifier: Blood and Marrow Transplantation Program )
0401M55207 ( Other Identifier: IRB, University of Minnesota )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Masonic Cancer Center, University of Minnesota
Study Sponsor  ICMJE Masonic Cancer Center, University of Minnesota
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Jeffrey Miller, MD Masonic Cancer Center, University of Minnesota
PRS Account Masonic Cancer Center, University of Minnesota
Verification Date December 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP